Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis

被引：28

作者：

Zhang, Shi-Ming ^{[1
]}

Zhu, Qing-Ge ^{[1
]}

Ding, Xiao-Xiao ^{[1
]}

Lin, Song ^{[1
]}

Zhao, Jing ^{[1
]}

Guan, Lei ^{[1
]}

Li, Ting ^{[1
]}

He, Bing ^{[1
]}

Zhang, Hu-Qin ^{[1
]}

机构：

[1] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Key Lab Biomed Informat Engn, Minist Educ, 28 Xianning West Rd, Xian 710049, Shaanxi, Peoples R China

来源：

CANCER MANAGEMENT AND RESEARCH | 2018年 / 10卷

基金：

美国国家科学基金会; 中国国家自然科学基金; 中国博士后科学基金;

关键词：

EGFR mutations; KRAS mutations; meta-analysis; non-small cell lung cancer; prognosis; resected; GROWTH-FACTOR RECEPTOR; POST-RECURRENCE SURVIVAL; MUTATION STATUS; GENE-MUTATIONS; ADJUVANT CHEMOTHERAPY; CLINICAL-FEATURES; JAPANESE PATIENTS; KI-67; EXPRESSION; ADENOCARCINOMA; IMPACT;

D O I：

10.2147/CMAR.S167578

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The prognostic value of EGFR and KRAS mutations in resected non-small cell lung cancer (NSCLC) has been reported. However, conflicting results were reported in these studies. The effect of mutations in these two genes in resected NSCLC remains controversial. Methods: We searched Internet databases for studies reporting disease-free survival (DFS) and overall survival (OS) in resected NSCLC patients with EGFR or KRAS mutations. A meta-analysis calculating the pooled hazard ratio (HR) for DFS and OS was used to measure the association of EGFR or KRAS mutations with the prognosis of patients after surgery. Results: A total of 9,635 patients from 32 studies were included in this analysis. The combined HR for EGFR mutations on DFS was 0.77 (95% CI 0.66-0.90, p=0.001) and on OS was 0.72 (95% CI 0.66-0.80, p<0.00001). In addition, the combined HR for KRAS mutations on DFS was 1.5 (95% CI 1.15-1.96, p=0.002) and on OS was 1.49 (95% CI 1.28-1.73, p<0.00001). Sensitivity analysis, subgroup analysis, and bias analysis proved the stability of the results. Conclusion: The analysis showed that EGFR mutations were significantly associated with DFS and OS. These findings indicated that surgically treated NSCLC patients with EGFR mutations were inclined to exhibit a prolonged DFS and OS. In addition, the results indicated that KRAS mutations predicted worse DFS and OS in patients with resected NSCLC.

引用

页码：3393 / 3404

页数：12

共 53 条

[1] American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].